Developer docs
API playgroundTry for free, no card

Search company profiles

Little Green Pharma

Full company profile

uuid0005lhu

Namestring
Little Green Pharma
Legal namestring
Little Green Pharma Ltd
Websiteurl
littlegreenpharma.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Little Green Pharma is an Australian-headquartered, vertically integrated medicinal cannabis producer listed on the ASX under ticker LGP. The company cultivates and manufactures pharmaceutical-grade cannabis oil formulations (including LGP Pure CBD 200, LGP Classic 10:10, and LGP Classic CBD 50) at TGA- and GMP-compliant Australian facilities and an EU-GMP-certified 21,500 m² cultivation and 4,000 m² manufacturing site in Odense, Denmark, acquired in 2021. Products are dispensed to patients via Australian pharmacies through the TGA Special Access Scheme and Authorised Prescriber pathway, and exported to nine countries across the UK and Europe through distribution partnerships.

The company serves three core customer segments: healthcare professionals (GPs, specialists, pharmacists, nurse practitioners) who prescribe medicinal cannabis and receive clinical education and prescribing support; patients (over 50,000 served globally since 2018), many with chronic pain, who access products via pharmacies with concession and compassionate access pricing; and pharmacies that dispense prescribed products. Revenue is generated through unit-priced product sales (reference pricing approximately A$150 per 50 mL bottle) under a pay-as-you-go model, supplemented by transactional revenue from international distribution partners.

Little Green Pharma operates a multi-channel go-to-market combining a direct field sales force of Medical Science Liaisons and territory-based Account Managers, a self-serve Medical Portal for healthcare professionals, a Perth-based Customer Care Team, and a distribution partner network for international markets. In January 2026, the company announced an all-stock merger with Cannatrek to create a combined entity with A$112 million in revenue, positioning the merged group as one of the largest vertically integrated cannabis businesses globally.

Short descriptiontext

Little Green Pharma is a vertically integrated Australian medicinal cannabis producer that cultivates, manufactures, and distributes pharmaceutical-grade cannabis oil products to patients across Australia and nine European countries via healthcare professionals and pharmacies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPerth, Australia
HQ citystring
Perth
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medicinal cannabis, cannabis-based medicines, pharmaceutical manufacturing, cannabis cultivation, EU-GMP manufacturing
Industry1 code
1Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
CodeCRANAFAIPrimaryYes
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medicinal Cannabis Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medicinal Cannabis Product Sales
TypeHardware Sales
Description

Revenue from sale of medicinal cannabis products including flower and oil-based formulations to patients through pharmacies in Australia and via distribution partnerships internationally. Products include CBD-dominant, balanced THC/CBD, and THC-dominant formulations.

businessofcannabis.com
2International Distribution
TypeTransaction Fee
Description

Revenue from distribution partnerships across 9 countries in the UK and Europe including Germany, UK, France, Poland, Spain, Denmark, Italy, with strategic positioning for Scandinavia and Portugal.

littlegreenpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details3 tiers
1Standard Pricing - LGP Classic 10:10
ModelUnit PricingBilling cadencePay-as-you-go
Notes

LGP Classic 10:10 50mL bottle costs $150. Average patient taking 1-1.5mL per day pays $3.00-$4.50/day, equating to $90-$135 per month. Pricing varies by product formulation (CBD-dominant, balanced, THC-dominant).

portal.littlegreenpharma.com
2Compassionate Access Program
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Free or 50% discounted product for patients demonstrating financial need. Company states: 'From our compassionate access scheme offering free or discounted product (at 50%).'

portal.littlegreenpharma.com
3Concession Pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Discounted pricing for concession card holders to improve patient accessibility to medicinal cannabis treatments.

portal.littlegreenpharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LGP Medical Portal
Description

Healthcare professional portal providing access to medicinal cannabis education, events, dispensing tools, and product information.

portal.littlegreenpharma.com
+1 more record
Core offering1 text field

Little Green Pharma is a vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes a range of pharmaceutical-grade cannabis-based medicines (CBD-dominant, balanced THC/CBD, and THC-dominant oil formulations) from facilities in Australia and Denmark. The company sells through Australian pharmacies to patients with valid TGA prescriptions and via international distribution partnerships across nine UK and European countries, while providing a Medical Portal for healthcare professionals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 50,000+ patients treated globally since 2018
+2 more records
Product overview1 text field

Little Green Pharma is a medicinal cannabis company offering a portfolio of cannabis-based medicines including three named oil products: LGP Pure CBD 200 (CBD-only), LGP Classic 10:10 (balanced 10:10 ratio), and LGP Classic CBD 50 (CBD-dominant). Products are manufactured at Australian and Danish facilities. The company provides a Medical Portal platform for healthcare professionals to access product information, education, and prescribing resources. Patient access programs include Compassionate Access (free/discounted products) and Concession Pricing.

Product and service1 record
1LGP Pure CBD 200
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Cannatrek
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff. The merger positions the entity as one of the largest vertically integrated cannabis businesses globally. Cannatrek founder Thomas Huppert (with 30+ years experience and $350M cumulative revenue at Cannatrek) becomes Non-Executive Director.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Cann Group Limited
TypeDirect peer
Description

Australian medicinal cannabis producer and manufacturer listed on the ASX (ASX: CAN). Directly comparable to LGP as a vertically integrated Australian medicinal cannabis company with cultivation, manufacturing and TGA-regulated distribution, competing for the same Australian prescriber and pharmacy channel.

2Bod Australia Limited
TypeDirect peer
Description

ASX-listed Australian medicinal cannabis and CBD wellness company (ASX: BDA) developing and distributing cannabis-based therapeutic products. Comparable to LGP in product format (oil-based formulations), target patient population and TGA-regulated distribution through healthcare professionals.

3Althea Group Holdings
TypeDirect peer
Description

Australian medicinal cannabis company (ASX: AGH) supplying a range of cannabis-based medicines to Australian patients via prescription. Closely comparable to LGP in business model, product mix (flower and oil), prescriber-focused go-to-market and pharmacy dispensing model.

4Cannatrek
TypeDirect peer
Description

Australian medicinal cannabis producer and the announced merger partner of Little Green Pharma. Directly comparable as an Australian vertically integrated cannabis business with cultivation, manufacturing and international ambitions (including Cannatrek Japan KK), and the most relevant peer given the pending merger combination.

5Tilray Brands
TypeBroad incumbent
Description

Global cannabis leader (NASDAQ: TLRY) with operations across Canada, US, Europe and Australia, including cultivation, processing and distribution of medical and adult-use cannabis. Comparable to LGP in medicinal cannabis product range, EU presence (Tilray has German supply) and pharmacy/wholesale distribution, but at much larger scale and broader portfolio.

6Aurora Cannabis
TypeBroad incumbent
Description

Canadian-licensed producer (NASDAQ: ACB) with EU-GMP certified cultivation in Canada and a European distribution platform including Germany. Comparable to LGP in EU-GMP certified medicinal cannabis production, German market exposure and multi-jurisdiction regulatory complexity, but operating at substantially larger scale with a broader product portfolio.

7GW Pharmaceuticals (Jazz Pharmaceuticals)
TypeBroad incumbent
Description

UK-based originator of approved cannabinoid medicines (Epidiolex/Epidyolex), acquired by Jazz Pharmaceuticals in 2021. Comparable to LGP as a pharmaceutical-grade cannabis medicine developer with EU/UK regulatory expertise and prescriber-channel distribution, but operating as part of a large pharma platform with approved prescription products rather than medicinal-cannabis oils.

8Canopy Growth Corporation
TypeBroad incumbent
Description

Canadian-licensed cannabis producer (NASDAQ: CGC) with global operations including Germany and Australia. Comparable to LGP in medicinal cannabis product formats, EU-GMP operations and pharmacy distribution, but at much greater scale with both medical and consumer-facing brands.

9Cresco Labs
TypeBroad incumbent
Description

US multi-state cannabis operator (OTC: CRLBF) with vertically integrated cultivation, manufacturing and dispensary operations. Comparable to LGP in vertically integrated cultivation-to-distribution model and pharmaceutical-grade product positioning, though operating primarily in the US adult-use and medical market rather than Australia/Europe.

10Zelira Therapeutics
TypeEmerging player
Description

Australian clinical-stage cannabinoid therapeutics company (ASX: ZLD) focused on pharmaceutical-grade cannabinoid medicines with global licensing partnerships. Comparable to LGP in Australian-listed medicinal cannabis positioning and clinical-evidence focus, though earlier-stage with a narrower product portfolio targeting specific indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Little Green Pharma

Medicinal Cannabis Pharmaceuticalslittlegreenpharma.com

Little Green Pharma is a vertically integrated Australian medicinal cannabis producer that cultivates, manufactures, and distributes pharmaceutical-grade cannabis oil products to patients across Australia and nine European countries via healthcare professionals and pharmacies.

What Little Green Pharma does

Little Green Pharma is an Australian-headquartered, vertically integrated medicinal cannabis producer listed on the ASX under ticker LGP. The company cultivates and manufactures pharmaceutical-grade cannabis oil formulations (including LGP Pure CBD 200, LGP Classic 10:10, and LGP Classic CBD 50) at TGA- and GMP-compliant Australian facilities and an EU-GMP-certified 21,500 m² cultivation and 4,000 m² manufacturing site in Odense, Denmark, acquired in 2021. Products are dispensed to patients via Australian pharmacies through the TGA Special Access Scheme and Authorised Prescriber pathway, and exported to nine countries across the UK and Europe through distribution partnerships.

The company serves three core customer segments: healthcare professionals (GPs, specialists, pharmacists, nurse practitioners) who prescribe medicinal cannabis and receive clinical education and prescribing support; patients (over 50,000 served globally since 2018), many with chronic pain, who access products via pharmacies with concession and compassionate access pricing; and pharmacies that dispense prescribed products. Revenue is generated through unit-priced product sales (reference pricing approximately A$150 per 50 mL bottle) under a pay-as-you-go model, supplemented by transactional revenue from international distribution partners.

Little Green Pharma operates a multi-channel go-to-market combining a direct field sales force of Medical Science Liaisons and territory-based Account Managers, a self-serve Medical Portal for healthcare professionals, a Perth-based Customer Care Team, and a distribution partner network for international markets. In January 2026, the company announced an all-stock merger with Cannatrek to create a combined entity with A$112 million in revenue, positioning the merged group as one of the largest vertically integrated cannabis businesses globally.

Little Green Pharma firmographics

Firmographics
Name
Little Green Pharma
Legal name
Little Green Pharma Ltd
Website
https://littlegreenpharma.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Little Green Pharma is a vertically integrated Australian medicinal cannabis producer that cultivates, manufactures, and distributes pharmaceutical-grade cannabis oil products to patients across Australia and nine European countries via healthcare professionals and pharmacies.
Ownership category
akta.pro rank

Little Green Pharma industry classification

Industry
Product category
Medicinal Cannabis Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

Keywords

  • Medicinal cannabis
  • Cannabis-based medicines
  • Pharmaceutical manufacturing
  • Cannabis cultivation
  • EU-GMP manufacturing

Where Little Green Pharma is headquartered

Location

Headquarters

HQ city
Perth
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Little Green Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Medicinal Cannabis Product Sales: Revenue from sale of medicinal cannabis products including flower and oil-based formulations to patients through pharmacies in Australia and via distribution partnerships internationally. Products include CBD-dominant, balanced THC/CBD, and THC-dominant formulations.
  2. International Distribution: Revenue from distribution partnerships across 9 countries in the UK and Europe including Germany, UK, France, Poland, Spain, Denmark, Italy, with strategic positioning for Scandinavia and Portugal.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Pricing - LGP Classic 10:10
Unit PricingPay-as-you-goCompassionate Access Program
Unit PricingPay-as-you-goConcession Pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Little Green Pharma product offering

Product offering

Core offering

Little Green Pharma is a vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes a range of pharmaceutical-grade cannabis-based medicines (CBD-dominant, balanced THC/CBD, and THC-dominant oil formulations) from facilities in Australia and Denmark. The company sells through Australian pharmacies to patients with valid TGA prescriptions and via international distribution partnerships across nine UK and European countries, while providing a Medical Portal for healthcare professionals.

Product overview

Little Green Pharma is a medicinal cannabis company offering a portfolio of cannabis-based medicines including three named oil products: LGP Pure CBD 200 (CBD-only), LGP Classic 10:10 (balanced 10:10 ratio), and LGP Classic CBD 50 (CBD-dominant). Products are manufactured at Australian and Danish facilities. The company provides a Medical Portal platform for healthcare professionals to access product information, education, and prescribing resources. Patient access programs include Compassionate Access (free/discounted products) and Concession Pricing.

Differentiator

Problem solved

Functional benefit

Brands

  • LGP Medical Portal: Healthcare professional portal providing access to medicinal cannabis education, events, dispensing tools, and product information.
  • Compassionate Access Scheme

Products and services

  • LGP Pure CBD 200

Quantifiable outcome

  • 50,000+ patients treated globally since 2018
  • +2 more outcomes

Companies that use Little Green Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Little Green Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Little Green Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CannatrekcoreStrategic or Co-development Partner · 21 January 2026Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff. The merger positions the entity as one of the largest vertically integrated cannabis businesses globally. Cannatrek founder Thomas Huppert (with 30+ years experience and $350M cumulative revenue at Cannatrek) becomes Non-Executive Director.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Little Green Pharma competitors and assessment

Company assessment

Direct peers

  • Cann Group Limited: Australian medicinal cannabis producer and manufacturer listed on the ASX (ASX: CAN). Directly comparable to LGP as a vertically integrated Australian medicinal cannabis company with cultivation, manufacturing and TGA-regulated distribution, competing for the same Australian prescriber and pharmacy channel.
  • Bod Australia Limited: ASX-listed Australian medicinal cannabis and CBD wellness company (ASX: BDA) developing and distributing cannabis-based therapeutic products. Comparable to LGP in product format (oil-based formulations), target patient population and TGA-regulated distribution through healthcare professionals.
  • Althea Group Holdings: Australian medicinal cannabis company (ASX: AGH) supplying a range of cannabis-based medicines to Australian patients via prescription. Closely comparable to LGP in business model, product mix (flower and oil), prescriber-focused go-to-market and pharmacy dispensing model.
  • Cannatrek: Australian medicinal cannabis producer and the announced merger partner of Little Green Pharma. Directly comparable as an Australian vertically integrated cannabis business with cultivation, manufacturing and international ambitions (including Cannatrek Japan KK), and the most relevant peer given the pending merger combination.

Broad incumbents

  • Tilray Brands: Global cannabis leader (NASDAQ: TLRY) with operations across Canada, US, Europe and Australia, including cultivation, processing and distribution of medical and adult-use cannabis. Comparable to LGP in medicinal cannabis product range, EU presence (Tilray has German supply) and pharmacy/wholesale distribution, but at much larger scale and broader portfolio.
  • Aurora Cannabis: Canadian-licensed producer (NASDAQ: ACB) with EU-GMP certified cultivation in Canada and a European distribution platform including Germany. Comparable to LGP in EU-GMP certified medicinal cannabis production, German market exposure and multi-jurisdiction regulatory complexity, but operating at substantially larger scale with a broader product portfolio.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): UK-based originator of approved cannabinoid medicines (Epidiolex/Epidyolex), acquired by Jazz Pharmaceuticals in 2021. Comparable to LGP as a pharmaceutical-grade cannabis medicine developer with EU/UK regulatory expertise and prescriber-channel distribution, but operating as part of a large pharma platform with approved prescription products rather than medicinal-cannabis oils.
  • Canopy Growth Corporation: Canadian-licensed cannabis producer (NASDAQ: CGC) with global operations including Germany and Australia. Comparable to LGP in medicinal cannabis product formats, EU-GMP operations and pharmacy distribution, but at much greater scale with both medical and consumer-facing brands.
  • Cresco Labs: US multi-state cannabis operator (OTC: CRLBF) with vertically integrated cultivation, manufacturing and dispensary operations. Comparable to LGP in vertically integrated cultivation-to-distribution model and pharmaceutical-grade product positioning, though operating primarily in the US adult-use and medical market rather than Australia/Europe.

Emerging players

  • Zelira Therapeutics: Australian clinical-stage cannabinoid therapeutics company (ASX: ZLD) focused on pharmaceutical-grade cannabinoid medicines with global licensing partnerships. Comparable to LGP in Australian-listed medicinal cannabis positioning and clinical-evidence focus, though earlier-stage with a narrower product portfolio targeting specific indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Little Green Pharma social profiles

Digital presence

Little Green Pharma compliance and trust

Trust signal

Compliance3 records

Little Green Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Little Green Pharma leadership team

Management profile

Number of profiles

Profiles9 records

Little Green Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Little Green Pharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Little Green Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Little Green Pharma

What does Little Green Pharma do?

Little Green Pharma is a vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes a range of pharmaceutical-grade cannabis-based medicines (CBD-dominant, balanced THC/CBD, and THC-dominant oil formulations) from facilities in Australia and Denmark. The company sells through Australian pharmacies to patients with valid TGA prescriptions and via international distribution partnerships across nine UK and European countries, while providing a Medical Portal for healthcare professionals.

Is Little Green Pharma a public or private company?

Little Green Pharma is a public company. It is classified as public and is currently operating.

When was Little Green Pharma founded?

Little Green Pharma was founded in 2016. It employs 51 to 100 people.

Where is Little Green Pharma based?

Little Green Pharma is headquartered in Perth, Australia, in the Oceania region.

How does Little Green Pharma make money?

Two revenue lines are on record. Medicinal Cannabis Product Sales are the primary driver. The others are international Distribution.

Who are Little Green Pharma's main competitors?

Direct peers on record are Cann Group Limited, Bod Australia Limited, Althea Group Holdings and Cannatrek. Broad incumbents are Tilray Brands, Aurora Cannabis, GW Pharmaceuticals (Jazz Pharmaceuticals), Canopy Growth Corporation and Cresco Labs. Zelira Therapeutics is listed as an emerging player.

Does Little Green Pharma have an API?

No public API is recorded for Little Green Pharma.

What industry is Little Green Pharma in?

Little Green Pharma's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business of Cannabis2026 Cannabis Consolidation: Mergers, Battles & PartnershipsHigh Tide's German subsidiary Remexian Pharma secured dual court victories against competitor Vayamed, with the Berlin Court of Appeal partially granting an injunction barring Vayamed from distributing disparaging statements about Remexian's Medicines Act compliance while Hamburg Regional Court issued a separate preliminary injunction against Malta-registered Dr Ansay Ltd for violations of Germany's Medicines Advertising Act. Australian medicinal cannabis companies Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff, positioning the entity as one of the largest vertically integrated cannabis businesses globally. Berlin-based Medios AG entered the medical cannabis market by securing exclusive distribution rights for Bedrocan's products across Germany, Spain, Belgium, Italy, and Austria, initially covering production from Bedrocan's EU-GMP certified facility in Denmark with expansion planned from 2027.GlobeNewswireMindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales PartnershipPharmAla completed the first sale of pharmaceutical-grade psilocybin from Mindset Pharma to Reset Mind Sciences, a subsidiary of Little Green Pharma. The sale occurs under an exclusive agreement, and Reset has received ethics approval for a psilocybin-assisted therapy trial for treatment-resistant depression. The companies expect this to mark the start of a fruitful partnership.ABCMedicinal cannabis company Little Green Pharma gets green light for psychedelic drug productionThe Western Australia Department of Health has granted Little Green Pharma a Schedule 9 licence to produce psilocybin for medical research, marking the company's first entry into the psychedelic market. This approval aims to address domestic supply shortages and support clinical trials targeting mental illnesses such as PTSD, anxiety, and depression. The development is viewed by experts as a significant step in advancing local psychiatric treatment research.PR NewswireLittle Green Pharma To Accelerate Growth Strategy With Acquisition of World-Class Production and Manufacturing Facility in DenmarkLittle Green Pharma Ltd has acquired a fully operational GMP medicinal cannabis cultivation and manufacturing facility in Northern Odense, Denmark, from Canopy Growth Corporation for C$20 million. The 21,500 m2 facility has the capacity to produce over 12 tonnes per annum of finished flower and is expected to provide LGP with significant product supply while expanding its European market presence. The acquisition positions LGP as the leading Australian medicinal cannabis producer and one of the largest cannabis production facilities in Europe.PR NewswireLittle Green Pharma beschleunigt Wachstumsstrategie mit dem Erwerb einer Weltklasse-Produktions- und Fertigungsanlage in DänemarkLittle Green Pharma Ltd (ASX: LGP) has acquired a fully operational GMP cultivation and production facility for medical cannabis in Odense, Denmark, from Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) for C$20 million. The 21,500 m² facility has an annual production capacity exceeding 12 tonnes of finished cannabis flowers, immediately supplying LGP with approximately 1 tonne of existing medical cannabis inventory. LGP, previously a cultivation-only operator, plans to build out distribution and marketing capabilities to serve EU and global markets, beginning with Australia and Germany, while the Danish facility targets registration of its first medical cannabis products for the Danish market by early 2022.PR NewswireLittle Green Pharma acelerará su estrategia de crecimientoLittle Green Pharma Ltd (ASX: LGP) has acquired a fully operational GMP-certified medicinal cannabis cultivation and manufacturing facility in Odense, Denmark, from Canopy Growth Corporation for approximately CAD $20 million. The facility spans 21,500 m² of cultivation space and 4,000 m² of GMP manufacturing space, with annual production capacity exceeding 12 tonnes of finished flower, addressing LGP's current inventory supply needs of approximately 1 tonne. LGP plans to expand the facility's services through a new sales and marketing division to serve global and EU markets, while preserving all existing jobs and growing its local workforce in Odense.PR NewswireLittle Green Pharma va accélérer sa stratégie de croissance grâce à l'acquisition d'un site de production et de fabrication de classe mondiale au DanemarkLittle Green Pharma Ltd (ASX: LGP) acquired a fully operational GMP therapeutic cannabis cultivation and manufacturing facility in Odense, Denmark, from Canopy Growth Corporation for CAD 20 million. The 21,500 m² cultivation facility and 4,000 m² GMP manufacturing plant have a combined production capacity exceeding 12 tonnes of finished cannabis flower per year. The acquisition makes LGP the first Australian therapeutic cannabis producer to own one of Europe's largest and highest-quality cannabis production facilities, enabling it to expand into European and global markets while strengthening supply to existing markets in Australia and Germany.PR NewswireUnprecedented international achievement for Panaxia: selected as one of the four main winners in the French government tender for regulation of the medical cannabis industryPanaxia Labs Israel, together with its partner Neuraxpharm, was selected as a primary supplier in a French government tender issued by ANSM for a two-year medical cannabis pilot program, joining three other global cannabis companies—Tilray, Aurora, and Little Green Pharma—as primary suppliers.GlobeNewswireLittle Green Pharma granted manufacturing permit from the Office of Drug ControlLittle Green Pharma received a Manufacture Permit from Australia's Office of Drug Control, valid until March 2021. The permit allows in-house extraction of cannabis extracts, reducing costs and improving efficiencies. LGP expects to begin first planting once its expanded cultivation permit is granted.GlobeNewswireUK Patients to Access First-Ever Export of Australian Medicinal Cannabis OilLittle Green Pharma exported its first shipment of medicinal cannabis products to the UK, distributed by Astral Health. The UK industry is forecast to grow to £1.05 billion by 2024, with 400,000 patients expected to be prescribed medicinal cannabis.